H. Lundbeck A/S

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, H. Lundbeck A/S sits in the top decile of US sponsors by registered trial count (#300 of 15,742 sponsors by registered trial count).

72 total trials 5 currently recruiting 47 completed top decile by trial count

H. Lundbeck A/S: 72 sponsored US clinical trials, 5 recruiting.

H. Lundbeck A/S sponsors 72 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 47 completed. 36 of these trials are in Phase 3-4 (later-stage) and 35 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Migraine, with 4 trials.

Top-decile sponsor footprint

H. Lundbeck A/S ranks in the top decile of sponsors by registered trial count (#300 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 26/100

47 of 63 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (74.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

72 total, page 2 of 2

COMPLETED Phase 1

Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700

NCT02333487
COMPLETED Phase 2

Investigating the Effect of Vortioxetine in Adult ADHD Patients

NCT02327013
COMPLETED Phase 3

Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

NCT02079246
COMPLETED Phase 3

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor

NCT02006654
COMPLETED Phase 3

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

NCT02006641
TERMINATED Phase 3

Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)

NCT01987960
COMPLETED Phase 1

Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia

NCT02202213
COMPLETED Phase 3

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

NCT01955161
COMPLETED Phase 3

Aripiprazole Once-monthly in Patients With Schizophrenia

NCT01959035
COMPLETED Phase 3

Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy

NCT01942785
TERMINATED Phase 3

Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder

NCT01944969
COMPLETED Phase 3

Brexpiprazole in Patients With Schizophrenia

NCT01810783
COMPLETED Phase 3

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT01838681
TERMINATED Phase 3

Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT01837797
COMPLETED Phase 3

Brexpiprazole in Patients With Acute Schizophrenia

NCT01810380
COMPLETED Phase 3

Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia

NCT01795547
COMPLETED Phase 1

Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia

NCT02202226
COMPLETED Phase 2

Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder

NCT01491035
COMPLETED Phase 2

Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia

NCT01377233
TERMINATED Phase 3

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

NCT00856661
TERMINATED Phase 2

Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression

NCT00771134
COMPLETED Phase 3

Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia

NCT00654706
← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 27
Phase 2 8
Phase 3 32
Phase 4 4

Therapeutic Areas

Migraine 4
Schizophrenia 3
Multiple System Atrophy 2
Chronic Migraine in Children 1
Congenital Adrenal Hyperplasia 1
Cushing's Disease 1
Schizoaffective Disorder 1
Episodic Migraine 1
Alzheimers Disease 1
Attention Deficit Hyperactivity Disorder 1

What is open in the H. Lundbeck A/S pipeline

5 recruiting of 72 indexed (7% open); 47 completed (65%).

Phase mix: 36 late (III/IV) vs 35 early (I/II) (balanced across stages).

Top condition: Migraine (4 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

H. Lundbeck A/S: open-pipeline peers nationwide

Peers matched on 72 registered trials and 7% open enrollment, not the therapeutic-area sidebar.

H. Lundbeck A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400 0%5%10%15%20%25% Total trials Recruiting share H. Lundbeck A/SSmith & NephewUniversity of California, BerkeleyDenver Health and Hospital AuthorityHugo W. Moser Research Institute at Kennedy KriegerGenentechBioCryst PharmaceuticalsWake Forest UniversityAgios Pharmaceuticals
H. Lundbeck A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

H. Lundbeck A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 72 trials (± recruiting share)

Sponsors near 7% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this H. Lundbeck A/S page

72 registered trials is a research-attention snapshot, not an endorsement of H. Lundbeck A/S or any single study.

  • 5 of H. Lundbeck A/S's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Migraine is the condition H. Lundbeck A/S studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Migraine trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

H. Lundbeck A/S pipeline card: 72 registered trials from official public datasets.Report a data error.